Filing Details

Accession Number:
0001104659-13-019400
Form Type:
4
Zero Holdings:
No
Publication Time:
2013-03-11 18:59:37
Reporting Period:
2013-03-07
Filing Date:
2013-03-11
Accepted Time:
2013-03-11 18:59:37
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1396814 Pacira Pharmaceuticals Inc. PCRX Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1306695 Sanderling Venture Partners Vi Co Investment Fund Lp C/O Sanderling Ventures
400 South El Camino Real, Suite 1200
San Mateo CA 94402
No No Yes No
1306717 Sanderling Venture Partners Vi Lp C/O Sanderling Ventures
400 South El Camino Real, Suite 1200
San Mateo CA 94402
No No Yes No
1429282 Partnership Limited Vi Sanderling C/O Sanderling Ventures
400 South El Camino Real, Suite 1200
San Mateo CA 94402
No No Yes No
1429283 Sanderling Vi Beteiligungs Gmbh & Co Kg C/O Sanderling Ventures
400 South El Camino Real, Suite 1200
San Mateo CA 94402
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2013-03-07 17,973 $2.69 900,535 No 4 X Direct
Common Stock Acquisiton 2013-03-07 629 $2.69 48,383 No 4 X Direct
Common Stock Acquisiton 2013-03-07 750 $2.69 57,646 No 4 X Direct
Common Stock Acquisiton 2013-03-07 17,839 $2.69 1,353,952 No 4 X Direct
Common Stock Disposition 2013-03-07 1,866 $25.92 898,669 No 4 S Direct
Common Stock Disposition 2013-03-07 66 $25.92 48,317 No 4 S Direct
Common Stock Disposition 2013-03-07 78 $25.92 57,568 No 4 S Direct
Common Stock Disposition 2013-03-07 1,852 $25.92 1,352,100 No 4 S Direct
Common Stock Acquisiton 2013-03-07 20,220 $13.44 918,889 No 4 X Direct
Common Stock Acquisiton 2013-03-07 708 $13.44 49,025 No 4 X Direct
Common Stock Acquisiton 2013-03-07 843 $13.44 58,411 No 4 X Direct
Common Stock Acquisiton 2013-03-07 20,069 $13.44 1,372,169 No 4 X Direct
Common Stock Disposition 2013-03-07 10,485 $25.92 908,404 No 4 S Direct
Common Stock Disposition 2013-03-07 368 $25.92 48,657 No 4 S Direct
Common Stock Disposition 2013-03-07 438 $25.92 57,973 No 4 S Direct
Common Stock Disposition 2013-03-07 10,407 $25.92 1,361,762 No 4 S Direct
Common Stock Disposition 2013-03-11 348,951 $27.86 559,453 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 X Direct
No 4 X Direct
No 4 X Direct
No 4 X Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 X Direct
No 4 X Direct
No 4 X Direct
No 4 X Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Common Stock Warrants (right to buy) Disposition 2013-03-07 17,973 $0.00 17,973 $2.69
Common Stock Common Stock Warrants (right to buy) Disposition 2013-03-07 629 $0.00 629 $2.69
Common Stock Common Stock Warrants (right to buy) Disposition 2013-03-07 750 $0.00 750 $2.69
Common Stock Common Stock Warrants (right to buy) Disposition 2013-03-07 17,839 $0.00 17,839 $2.69
Common Stock Common Stock Warrants (right to buy) Disposition 2013-03-07 20,220 $0.00 20,220 $13.44
Common Stock Common Stock Warrants (right to buy) Disposition 2013-03-07 708 $0.00 708 $13.44
Common Stock Common Stock Warrants (right to buy) Disposition 2013-03-07 843 $0.00 843 $13.44
Common Stock Common Stock Warrants (right to buy) Disposition 2013-03-07 20,069 $0.00 20,069 $13.44
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2009-01-22 2014-01-21 No 4 X Direct
0 2009-01-22 2014-01-21 No 4 X Direct
0 2009-01-22 2014-01-21 No 4 X Direct
0 2009-01-22 2014-01-21 No 4 X Direct
0 2010-12-29 2017-12-29 No 4 X Direct
0 2010-12-29 2017-12-29 No 4 X Direct
0 2010-12-29 2017-12-29 No 4 X Direct
0 2010-12-29 2017-12-29 No 4 X Direct
Footnotes
  1. The securities are held directly by Sanderling Venture Partners VI, L.P. The address for Sanderling Venture Partners VI , L.P. is c/o Sanderling Ventures, 400 South El Camino Real, Suite 1200, San Mateo, CA 94402.
  2. The securities are held by Sanderling VI Beteiligungs GmbH & Co. KG. The address for Sanderling VI Beteiligungs GmbH & Co. KG is c/o Sanderling Ventures, 400 South El Camino Real, Suite 1200, San Mateo, CA 94402.
  3. The securities are held directly by Sanderling VI Limited Partnership. The address for Sanderling VI Limited Partnership is c/o Sanderling Ventures, 400 South El Camino Real, Suite 1200, San Mateo, CA 94402.
  4. The securities are held directly by Sanderling Venture Partners VI Co-Investment Fund, L.P. The address for Sanderling Venture Partners VI Co-Investment Fund, L.P. is c/o Sanderling Ventures, 400 South El Camino Real, Suite 1200, San Mateo, CA 94402.
  5. Fred Middleton, a member of the Board of Directors of the Issuer, is a managing director of Middleton, McNeil, Mills & Associates VI, LLC, which has the ultimate voting and investment power over shares held of record by Sanderling Venture Partners VI, L.P., Sanderling VI Beteiligungs GmbH & Co. KG, Sanderling VI Limited Partnership and Sanderling Venture Partners VI Co-Investment Fund, L.P. and he may be deemed to have voting and investment power over shares held of record by Sanderling Venture Partners VI, L.P., Sanderling VI Beteiligungs GmbH & Co. KG, Sanderling VI Limited Partnership and Sanderling Venture Partners VI Co-Investment Fund, L.P.
  6. On March 7, 2013, the reporting person exercised a warrant to purchase 17,973 shares of PCRX common stock for $2.69 per share. The reporting person paid the exercise price on a cashless basis, resulting in PCRX's withholding of 1,866 of the warrant shares to pay the exercise price and issuing to the reporting person the remaining 16,107 shares. PCRX also paid $19.35 to the reporting person in lieu of a fractional share.
  7. On March 7, 2013, the reporting person exercised a warrant to purchase 629 shares of PCRX common stock for $2.69 per share. The reporting person paid the exercise price on a cashless basis, resulting in PCRX's withholding of 66 of the warrant shares to pay the exercise price and issuing to the reporting person the remaining 563 shares. PCRX also paid $18.71 to the reporting person in lieu of a fractional share.
  8. On March 7, 2013, the reporting person exercised a warrant to purchase 750 shares of PCRX common stock for $2.69 per share. The reporting person paid the exercise price on a cashless basis, resulting in PCRX's withholding of 78 of the warrant shares to pay the exercise price and issuing to the reporting person the remaining 672 shares. PCRX also paid $4.26 to the reporting person in lieu of a fractional share.
  9. On March 7, 2013, the reporting person exercised a warrant to purchase 17,839 shares of PCRX common stock for $2.69 per share. The reporting person paid the exercise price on a cashless basis, resulting in PCRX's withholding of 1,852 of the warrant shares to pay the exercise price and issuing to the reporting person the remaining 15,987 shares. PCRX also paid $16.93 to the reporting person in lieu of a fractional share.
  10. On March 7, 2013, the reporting person exercised a warrant to purchase 20,220 shares of PCRX common stock for $13.44 per share. The reporting person paid the exercise price on a cashless basis, resulting in PCRX's withholding of 10,485 of the warrant shares to pay the exercise price and issuing to the reporting person the remaining 9,735 shares. PCRX also paid $14.40 to the reporting person in lieu of a fractional share.
  11. On March 7, 2013, the reporting person exercised a warrant to purchase 708 shares of PCRX common stock for $13.44 per share. The reporting person paid the exercise price on a cashless basis, resulting in PCRX's withholding of 368 of the warrant shares to pay the exercise price and issuing to the reporting person the remaining 340 shares. PCRX also paid $23.04 to the reporting person in lieu of a fractional share.
  12. On March 7, 2013, the reporting person exercised a warrant to purchase 843 shares of PCRX common stock for $13.44 per share. The reporting person paid the exercise price on a cashless basis, resulting in PCRX's withholding of 438 of the warrant shares to pay the exercise price and issuing to the reporting person the remaining 405 shares. PCRX also paid $23.04 to the reporting person in lieu of a fractional share.
  13. On March 7, 2013, the reporting person exercised a warrant to purchase 20,069 shares of PCRX common stock for $13.44 per share. The reporting person paid the exercise price on a cashless basis, resulting in PCRX's withholding of 10,407 of the warrant shares to pay the exercise price and issuing to the reporting person the remaining 9,662 shares. PCRX also paid $22.08 to the reporting person in lieu of a fractional share.